A humanized monoclonal antibody against respiratory syncytial virus (palivizumab) inhibits RSV-induced neurogenic-mediated inflammation in rat airways

Pediatric Research

Volumn 47, Issue 3, 2000, Pages 351-356

  Piedimonte, Giovanni ^a   King, Katherine A ^a   Holmgren, Nils L ^a   Bertrand, Pablo J ^a   Rodriguez, Maria M ^a   Hirsch, Robert L ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; SUBSTANCE P RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HIGH RISK PATIENT; INFECTION PREVENTION; INOCULATION; MALE; NEUROGENIC INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; RAT; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; VIRUS INFECTION;

EID: 0033997504     PISSN: 00313998     EISSN: None     Source Type: Journal    
DOI: 10.1203/00006450-200003000-00011     Document Type: Article

References (24)

1. Hall CB 1998 Respiratory syncytial virus. In: Feigin RD, Cherry JD (eds) Textbook of Pediatric Infectious Diseases. WB Saunders, Philadelphia, pp 2084-2111
2. Eigen H 1999 The RSV-asthma link: the emerging story. J Pediatr 135:S1-S50
3. Stein RT, Sherril D, Morgan WJ, Holberg CJ, Halonen M, Taussig LM, Wright AL, Martinez FD 1999 Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 354:541-545
4. Piedimonte G 1995 Tachykinin peptides, receptors, and peptidases in airway disease. Exp Lung Res 21:809-834
5. Piedimonte G, Nadel JA 1996 Role of peptidases in airway defense mechanisms. In: Chretien J, Dusser D (eds) Airways and Environment: From Injury to Repair. Marcel Dekker, New York, pp 123-153
6. Barnes PJ 1992 Neurogenic inflammation and asthma. J Asthma 29:165-180
7. Piedimonte G, Rodriguez MM, King KA, McLean S, Jiang X 1999 Respiratory syncytial virus upregulates expression of the substance P receptor in rat lungs. Am J Physiol 277:L831-L840
8. Piedimonte G, King KA, Perez Z, Jiang X 1999 Respiratory syncytial virus (RSV) causes long-term potentiation of neurogenic inflammation in rat airways. Am J Respir Crit Care Med 159:A245(abstr)
9. The PREVENT Study Group 1997 Reduction of respiratory syncytial virus hospitalizalion among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 99:93-99
10. The IMpact-RSV Study Group 1998 Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102:531-537
11. Piedimonte G, Pickles RJ, Lehmann JR, McCarty D, Costa DL, Boucher RC 1997 Replication-deficient adenoviral vector for gene transfer potentiates airway neurogenic inflammation. Am J Respir Cell Mol Biol 16:250-258
12. Routledge EG, McQuillin J, Samson ACR, Toms GL 1985 The development of monoclonal antibodies to respiratory syncytial virus and their use in diagnosis by indirect immunofluorescence. J Med Virol 15:305-320
13. Piedimonte G, Nadel JA, Umeno E, McDonald DM 1990 Sendai virus infection potentiates neurogenic inflammation in the rat trachea. J Appl Physiol 68:754-760
14. Piedimonte G, McDonald DM, Nadel JA 1990 Glucocorticoids inhibit neurogenic plasma extravasation and prevent virus-potentiated extravasation in the rat trachea. J Clin Invest 86:1409-1415
15. Prince GA, Jenson AB, Horswood RL 1978 The pathogenesis of respiratory syncytial virus infection in cotton rats. Am J Pathol 93:771-792
16. Saria A, Lundberg JM, Skofitsch G, Lembeck F 1983 Vascular protein leakage in various tissues induced by substance P, capsaicin, bradykinin, serotonin, histamine, and by antigen challenge. Naunyn Schmiedebergs Arch Pharmacol 324:212-218
17. Holzer P 1991 Capsaicin: cellular targets, mechanisms of action, and selectivity for thin sensory neurons. Pharmacol Rev 43:143-201
18. Siber GR, Leombruno D, Leszczynski J, McIver J, Bodkin D, Gonin R, Thompson CM, Walsh EE, Piedra PA, Hemming VG, Prince GA 1994 Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin. J Infect Dis 169:1368-1373
19. Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, Dormitzer M, O'Grady J, Koenig S, Tamura JK, Woods R, Bansal G, Couchenour D, Tsao E, Hall WC, Young JF 1997 Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus (RSV). J Infect Dis 176:1215-1224
20. Zar JH 1984 Two-Factor Analysis of Variance. Biostatistical Analysis. Prentice-Hall, Inc, Englewood Cliffs, NJ, pp 206-235
21. Wallenstein S, Zucker CL, Fleiss JL 1980 Some statistical methods useful in circulation research. Circ Res 47:1-9
22. Groothuis JR, Simoes EA,. Levin MJ, Hall CB, Long CE, Rodriguez WJ, Arrobio J, Meissner HC, Fulton DR, Welliver RC, Tristram DA, Siber GR, Prince GA. Van Raden M, Hemming VG 1993 Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med 329:1524-1530
23. Rodriguez WJ, Gruber WC, Welliver RC, Groothuis JR, Simoes EAF, Meissner HC, Hemming VG, Levin MJ, Hall CB, Lepow ML, Rosas AJ, Robertsen C, Kramer AA 1997 Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at risk for severe RSV infections. Pediatrics 99:454-461
24. Malley R, DeVincenzo J, Ramilo O, Dennehy PH, Meissner HC, Gruber WC, Sanchez PJ, Jafri H, Balsley J, Carlin D, Buckingham S, Vernacchio L, Ambrosino DM 1998 Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J Infect Dis 178:1555-1561